Published in Ir J Med Sci on June 01, 1976
Echocardiography in chronic heart failure in the community. Q J Med (1993) 7.64
Primary non-compliance with prescribed medication in primary care. BMJ (1993) 6.80
Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ (1989) 4.76
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
Association of road-traffic accidents with benzodiazepine use. Lancet (1998) 4.01
The endoscopic breast augmentation: the transumbilical insertion of saline-filled breast implants. Plast Reconstr Surg (1993) 3.45
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol (1977) 3.13
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ (1996) 2.51
Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ (1997) 2.39
Introducing a drug formulary to general practice--effects on practice prescribing costs. J R Coll Gen Pract (1987) 2.24
Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol (1989) 2.06
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut (1997) 1.98
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
A double-blind placebo-controlled trial of theophylline in general practice. Br J Clin Pract (1991) 1.93
Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur J Clin Pharmacol (1989) 1.88
Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med (1994) 1.86
Is maintenance digoxin necessary in patients with sinus rhythm? Lancet (1979) 1.86
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet (1973) 1.68
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
An epidemiological study of digoxin prescribing in general practice. J R Coll Gen Pract (1986) 1.66
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet (1979) 1.66
Simultaneous measurement of cardiac output and its distribution with microspheres in the rat. Cardiovasc Res (1976) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther (1976) 1.62
Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax (1993) 1.51
beta-Adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol (1978) 1.50
Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol (1989) 1.48
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Contribution of the vagus to the haemodynamic responses following intravenous boluses of isoprenaline. Br J Clin Pharmacol (1983) 1.44
Adverse reactions and interactions with beta-adrenoceptor blocking drugs. Med Toxicol (1987) 1.44
Digoxin compliance in patients from general practice. Br J Clin Pharmacol (1978) 1.38
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem (1983) 1.38
Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. Br J Clin Pharmacol (1986) 1.38
Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Br J Clin Pharmacol (1993) 1.37
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol (1973) 1.36
Plasma concentrations and the time-course of beta blockade due to propranolol. Clin Pharmacol Ther (1975) 1.36
Brucellosis in Northern Ireland. A serological survey. J Hyg (Lond) (1969) 1.34
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis (1985) 1.31
Measurement of theophylline in plasma by high performance liquid chromatography. Br J Clin Pharmacol (1976) 1.31
Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol (1988) 1.31
Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. Q J Med (1989) 1.31
Investigation of diurnal changes in the disposition of theophylline. Br J Clin Pharmacol (1983) 1.29
Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects. Br J Clin Pharmacol (1989) 1.29
Measurement of plasma mexiletine concentrations. Postgrad Med J (1977) 1.28
Variability in prescription drug utilization: issues for research. CMAJ (1996) 1.24
Theophylline kinetics in relation to age: the importance of smoking. Br J Clin Pharmacol (1980) 1.23
Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther (1983) 1.22
Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM (1995) 1.21
Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline. Thorax (1992) 1.21
Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade. Eur J Clin Pharmacol (1989) 1.21
Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis (1989) 1.20
Plasma theophylline concentrations following the oral administration of microcrystalline theophylline and a new sustained-release theophylline preparation to normal subjects. Eur J Clin Pharmacol (1980) 1.20
Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine. Br J Clin Pharmacol (1983) 1.19
Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax (1995) 1.19
Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood. Br J Clin Pharmacol (1988) 1.19
Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway. Br J Clin Pharmacol (1988) 1.17
A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol (1991) 1.17
Adrenoceptor blocking drugs: clinical pharmacology and therapeutic use. Drugs (1979) 1.17
Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease. Br J Clin Pharmacol (1984) 1.15
Quinidine-rifampin interaction. N Engl J Med (1981) 1.14
Measurement of partial agonist activity of pindolol. Clin Pharmacol Ther (1981) 1.13
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax (1995) 1.12
Vagal activity is increased during intravenous isoprenaline infusion in man. Br J Clin Pharmacol (1984) 1.11
Comparative trial of propranolol and practolol in hyperthyroidism. Br J Clin Pharmacol (1975) 1.11
The role of the thyroid in the control of heart-rate. Lancet (1968) 1.10
Phenytoin-theophylline interaction. N Engl J Med (1982) 1.10
General practitioners' use of non-steroidal anti-inflammatory drugs in Tayside and Fife regions. J R Soc Med (1992) 1.10
A comparison of verapamil and digoxin in the treatment of atrial fibrillation. Eur Heart J (1987) 1.10
The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J (1977) 1.09
Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology (1988) 1.08
Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol (1982) 1.08
Central effects of single oral doses of propranolol in man. Br J Clin Pharmacol (1984) 1.07